Cargando…
Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675468/ https://www.ncbi.nlm.nih.gov/pubmed/36214223 http://dx.doi.org/10.1172/jci.insight.160398 |
_version_ | 1784833380259463168 |
---|---|
author | Sidiropoulos, Dimitrios N. Stein-O’Brien, Genevieve L. Danilova, Ludmila Gross, Nicole E. Charmsaz, Soren Xavier, Stephanie Leatherman, James Wang, Hao Yarchoan, Mark Jaffee, Elizabeth M. Fertig, Elana J. Ho, Won Jin |
author_facet | Sidiropoulos, Dimitrios N. Stein-O’Brien, Genevieve L. Danilova, Ludmila Gross, Nicole E. Charmsaz, Soren Xavier, Stephanie Leatherman, James Wang, Hao Yarchoan, Mark Jaffee, Elizabeth M. Fertig, Elana J. Ho, Won Jin |
author_sort | Sidiropoulos, Dimitrios N. |
collection | PubMed |
description | Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on static metrics, such as discrete cell-type abundances, based on canonical markers and/or restrictive gating strategies. To overcome this limitation, we applied single-cell trajectory inference and nonnegative matrix factorization methods to CyTOF data to trace the dynamics of T cell states. In the setting of cancer immunotherapy, we showed that patient-specific summaries of continuous phenotypic shifts in T cells could be inferred from peripheral blood–derived CyTOF mass cytometry data. We further illustrated that transfer learning enabled these T cell continuous metrics to be used to estimate patient-specific cell states in new sample cohorts from a reference patient data set. Our work establishes the utility of continuous metrics for CyTOF analysis as tools for translational discovery. |
format | Online Article Text |
id | pubmed-9675468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-96754682022-11-21 Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials Sidiropoulos, Dimitrios N. Stein-O’Brien, Genevieve L. Danilova, Ludmila Gross, Nicole E. Charmsaz, Soren Xavier, Stephanie Leatherman, James Wang, Hao Yarchoan, Mark Jaffee, Elizabeth M. Fertig, Elana J. Ho, Won Jin JCI Insight Technical Advance Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on static metrics, such as discrete cell-type abundances, based on canonical markers and/or restrictive gating strategies. To overcome this limitation, we applied single-cell trajectory inference and nonnegative matrix factorization methods to CyTOF data to trace the dynamics of T cell states. In the setting of cancer immunotherapy, we showed that patient-specific summaries of continuous phenotypic shifts in T cells could be inferred from peripheral blood–derived CyTOF mass cytometry data. We further illustrated that transfer learning enabled these T cell continuous metrics to be used to estimate patient-specific cell states in new sample cohorts from a reference patient data set. Our work establishes the utility of continuous metrics for CyTOF analysis as tools for translational discovery. American Society for Clinical Investigation 2022-10-10 /pmc/articles/PMC9675468/ /pubmed/36214223 http://dx.doi.org/10.1172/jci.insight.160398 Text en © 2022 Sidiropoulos et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Technical Advance Sidiropoulos, Dimitrios N. Stein-O’Brien, Genevieve L. Danilova, Ludmila Gross, Nicole E. Charmsaz, Soren Xavier, Stephanie Leatherman, James Wang, Hao Yarchoan, Mark Jaffee, Elizabeth M. Fertig, Elana J. Ho, Won Jin Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title | Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title_full | Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title_fullStr | Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title_full_unstemmed | Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title_short | Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
title_sort | integrated t cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675468/ https://www.ncbi.nlm.nih.gov/pubmed/36214223 http://dx.doi.org/10.1172/jci.insight.160398 |
work_keys_str_mv | AT sidiropoulosdimitriosn integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT steinobriengenevievel integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT danilovaludmila integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT grossnicolee integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT charmsazsoren integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT xavierstephanie integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT leathermanjames integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT wanghao integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT yarchoanmark integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT jaffeeelizabethm integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT fertigelanaj integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials AT howonjin integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials |